Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer

被引：0
作者：
Yue Xi
Ting Li
Yun Xi
Xinyi Zeng
Ying Miao
Rui Guo
Min Zhang
Biao Li
机构：
[1] Ruijin Hospital,Department of Nuclear Medicine
[2] Shanghai Jiao Tong University School of Medicine,Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics
[3] Collaboration Innovation Center for Molecular Imaging of Precision Medicine,undefined
[4] Ruijin Center,undefined
[5] National Research Center for Translational Medicine at Shanghai,undefined
[6] Ruijin Hospital,undefined
[7] Shanghai Jiao Tong University School of Medicine,undefined
来源：
Cancer Cell International | / 22卷
关键词：
Triple-negative breast cancer; hENT1; miR-143; Combination therapy; Gemcitabine resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 344 条
[1]  
Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA A Cancer J Clin. 68 394-424
[2]  
Ferlay J(2011)Clinical practice. Breast-cancer screening N Engl J Med. 365 1025-32
[3]  
Soerjomataram I(2011)Breast cancer statistics, 2011 CA Cancer J Clin 61 409-418
[4]  
Siegel RL(2015)Global cancer statistics, 2012 CA Cancer J Clin 65 87-108
[5]  
Torre LA(2005)Global trends in breast cancer incidence and mortality 1973–1997 Int J Epidemiol 34 405-412
[6]  
Jemal A(1994)Cancer in developing countries CA 44 81-90
[7]  
Warner E(2006)Use of statistics to assess the global burden of breast cancer Breast J 12 S70-80
[8]  
DeSantis C(2018)Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing Cell 173 879-93.e13
[9]  
Siegel R(2010)Triple-negative breast cancer N Engl J Med 363 1938-1948
[10]  
Bandi P(2007)Triple-negative breast cancer: clinical features and patterns of recurrence Clin Cancer Res 13 4429-4434
12345678910